A recent meta‑analysis published in JAMA Network Open examined 110 randomized clinical trials involving more than 22,000 patients who received the injectable antibiotic cefepime or another beta‑lactam drug. The review found that 778 deaths occurred among the 11,726 patients treated with cefepime, representing a 6.6% mortality rate, compared with a 6.2% rate for patients given alternative antibiotics.
Key Findings
Using a Bayesian statistical approach, the investigators reported a 94.4% probability that cefepime is linked to higher all‑cause mortality than other beta‑lactam agents. When the analysis was limited to the 73 peer‑reviewed trials, that probability rose to 98.6%.
The association was strongest in adult patients, particularly those treated for febrile neutropenia—a serious condition marked by fever and dangerously low white‑blood‑cell counts. Children appeared to be less affected, and the overall trend was less pronounced in other infection types such as pneumonia, urinary‑tract infections, and meningitis.
Possible Explanations
Researchers noted several factors that could contribute to the observed mortality signal. Inadequate drug levels might fail to eradicate the infection, while excessively high concentrations can cause neurotoxicity, leading to confusion, decreased consciousness, or seizures—especially in older adults or patients with impaired kidney function.
Dr. Marc Siegel, senior medical analyst at Fox News, emphasized that the study highlights the importance of re‑examining dosing strategies. “Both under‑dosing and over‑dosing—rather than the drug itself—may be more closely linked to poorer outcomes,” he said. Siegel also suggested that artificial‑intelligence tools could help clinicians determine the optimal dose for individual patients.
Clinical Implications
Cefepime remains a widely used broad‑spectrum antibiotic for serious bacterial infections in hospitalized settings because of its effectiveness against a broad range of pathogens. The study’s authors did not call for discontinuation of the drug. Instead, they recommended that clinicians exercise heightened vigilance when prescribing cefepime, particularly for vulnerable populations, and that professional societies develop clearer dosing guidelines.
The analysis also acknowledged limitations. The included trials varied in design, patient demographics, dosing regimens, and comparator antibiotics, with some studies dating back several decades. Moreover, the meta‑analysis identified an association, not a definitive causal relationship, between cefepime and mortality.
What Patients Should Know
Patients receiving cefepime should be monitored closely for signs of neurotoxicity, especially if they are older, have kidney disease, or are being treated for febrile neutropenia. Discuss any concerns about dosing or side effects with the treating physician, and ask whether alternative antibiotics might be appropriate for their specific condition.
Overall, the findings underscore the need for ongoing research and updated clinical guidance to ensure that the benefits of cefepime outweigh its risks for each individual patient.
Original reporting: Fox News (HLL/CB) — read the source article.
